Reprogramming of bivalent chromatin states in NRAS mutant melanoma suggests PRC2 inhibition as a therapeutic strategy
Christopher Terranova(The University of Texas MD Anderson Cancer Center), Kunal Rai(The University of Texas MD Anderson Cancer Center), Ayush T. Raman(National Institutes of Health), Anand K. Singh(The University of Texas MD Anderson Cancer Center), Chang‐Jiun Wu, Elias Orouji(The University of Texas MD Anderson Cancer Center), Kaifu Chen(Boston Children's Hospital), Archit K. Ghosh(The University of Texas MD Anderson Cancer Center), Mayinuer Maitituoheti(The University of Texas MD Anderson Cancer Center), Khalida Wani(The University of Texas MD Anderson Cancer Center), Rossana Lazcano(The University of Texas MD Anderson Cancer Center), Sharmistha Sarkar(The University of Texas MD Anderson Cancer Center), Dongyu Zhao(Peking University), Jonathan E. Schulz(The University of Texas MD Anderson Cancer Center), Alexander J. Lazar(The University of Texas MD Anderson Cancer Center), Chantale Bernatchez(BMC Software (United States)), Samia Khan(The University of Texas MD Anderson Cancer Center), Junna Oba(Ehime University), Wei‐Lien Wang(The University of Texas MD Anderson Cancer Center), Katarzyna Tomczak(Postgraduate School of Molecular Medicine), Praveen Barrodia(The University of Texas MD Anderson Cancer Center), Caitlin Creasy(The University of Texas MD Anderson Cancer Center), Scott E. Woodman(The University of Texas MD Anderson Cancer Center), Ming Tang(AstraZeneca (United States)), Lauren E. Haydu(The University of Texas MD Anderson Cancer Center)
Cited by 31
Related Papers
An Integrated TCGA Pan-Cancer Clinical Data Resource to Drive High-Quality Survival Outcome Analytics
|Cell|2018|4k
Review The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge
|Współczesna Onkologia|2015|3.5k
Oncogenic Signaling Pathways in The Cancer Genome Atlas
|Cell|2018|3.4k